Immunocore Holdings plc Stock News

Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.

Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne

The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after met

Immunocore to present at Oppenheimer's 32 nd Annual Healthcare Conference

Immunocore (IMCR) said a committee of the European Medicines Agency ((EMA)) recommended the approval of its drug Kimmtrak (tebentafusp) to treat HLA-A 02:01-positive adult patients…

Immunocore to present at the SVB Leerink Global Healthcare Conference

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About 3 new molecular entities, or NMEs, were approved during the month, including Immunocore Holdings plc''s (NASDAQ: IMCR ) Kimmtrak for certain patients with advanced eye melanoma and Pfizer, Inc.''s (NYSE: PFE ) atopic dermatitis treatment Cibinqo. NME approval is an important indicator to measure innovation in drug research. NME approvals totaled 50 in 2021, almost equaling the numbers of the previous year. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN )- Sanofi (NASDAQ: SNY ), however, failed to get the nod for expanding the Libtayo label to include cervical cancer. Pfizer also faced rejection for its pediatric growth hormone deficiency treatment Somatrogon. A PDUFA date is the date/period by which the Food and Drug Administration is required to announce its verdict on a sponsor company''s regulatory application. This will determine the fate of millions of dollars invested in developing the treatment from the preclinical-stage to clinical testing.

Immunocore''s (IMCR) medicine Kimmtrak (tebentafusp-tebn) was approved by the U.S

Immunocore to present at the 40 th Annual J.P. Morgan Healthcare Conference

Shares of Immunocore Holdings plc (NASDAQ:IMCR) were up 13.2% during trading on Tuesday . The company traded as high as $31.23 and last traded at $31.23. Approximately 3,519 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 74,773 shares. The stock had previously closed at $27.58. A number []

Immunocore Holdings Plc (NASDAQ: IMCR ) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors . IMC-C103C was developed using the Company''s ImmTAC technology platform and is being developed in partnership with Genentech , a member of Roche Holdings AG (OTC: RHHBY ). IMC-C103C demonstrated a manageable safety profile. The most common treatment-related adverse events were cytokine release … Full story available on Benzinga.com

Geode Capital Management LLC bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,997 shares of the companys stock, valued at approximately $234,000. A number of other hedge funds have also recently []

PRESS RELEASE

Press Release

PRESS RELEASE